Nabiximols
NERVOUS SYSTEM
Also known as: cannabinoids, GW-1000, nabidiolex, sativex, tetranabinex
Data last refreshed: (DrugCentral release 2024-11-01)
Key facts
Nabiximols is a drug catalogued in DrugCentral. Recorded indications include Muscle Spasticity due to Multiple Sclerosis.
- Indications: Muscle Spasticity due to Multiple Sclerosis.
- ATC code: N02BG10 (Other analgesics and antipyretics).
- Molecular formula: C42H60O4; molecular weight 628.94 g/mol.
Indications & contraindications
Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).
Indications (1)
- Muscle Spasticity due to Multiple Sclerosis
ATC classification
| ATC code | Therapeutic hierarchy |
|---|---|
N02BG10 | NERVOUS SYSTEM › ANALGESICS › OTHER ANALGESICS AND ANTIPYRETICS › Other analgesics and antipyretics |
Reported adverse-event signals
Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.
| MedDRA term | LLR |
|---|---|
| COVID-19 | 185.6 |
| Multiple sclerosis relapse | 167.5 |
| Lymphopenia | 66.2 |
| Urinary tract infection | 57.6 |
| Cystitis noninfective | 55.6 |
| Muscle spasticity | 52.3 |
| Multiple sclerosis | 46.3 |
| SARS-CoV-2 antibody test negative | 46.0 |
| Progressive multifocal leukoencephalopathy | 29.7 |
| Sensory disturbance | 28.9 |
| Vitamin D decreased | 28.8 |
Chemical structure
| Molecular formula | C42H60O4 |
|---|---|
| Molecular weight | 628.94 g/mol |
| CAS number | 56575-23-6 |
| InChIKey | — |
| PubChem CID | 9852188 |
Frequently asked questions
Answers are generated from the structured data on this page, not written by hand.
What is Nabiximols used for?
DrugCentral lists the following indications for Nabiximols: Muscle Spasticity due to Multiple Sclerosis.
What is the chemical formula of Nabiximols?
Nabiximols has the molecular formula C42H60O4 and a molecular weight of 628.94 g/mol.
Browse: all drugs starting with N · drug guides by category · protein targets A–Z.
Sources
- DrugCentral drug card 4793 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
- ChEMBL CHEMBL3833333 — compound record and bioactivity
- PubChem CID 9852188 — chemical identifiers
- DrugBank DB14011 — drug record
- FDA UNII K4H93P747O — substance identity
- FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.